Table 2.
Treatment Modality | Personal Preference (%) |
Locally Available (%) |
Would Try First (%)a |
Would Not Be Effective (%) |
Believe Insurance Will Cover (%) |
---|---|---|---|---|---|
Residential Treatment | 31.9 | 46.5 | 9.8 | 14.8 | 9.8 |
One-on-One Counseling | 53.8 | 60.8 | 17.1 | 5.6 | 21.0 |
Cognitive Behavioral Therapy | 31.4 | 36.4 | 5.1 | 9.2 | 13.4 |
Group Counseling | 27.5 | 54.9 | 4.2 | 13.7 | 14.0 |
Intensive Outpatient | 17.1 | 24.6 | 0.6 | 7.6 | 7.0 |
Detox - Inpatient | 25.5 | 33.9 | 5.9 | 12.9 | 7.3 |
Detox - Outpatient | 25.2 | 31.7 | 5.1 | 11.5 | 6.4 |
Factor 1 (counseling/detox) | 80.7 | 74.5 | 47.6 | 43.7 | 28.9 |
Buprenorphine | 26.6 | 33.3 | 9.0 | 24.4 | 12.0 |
Methadone | 16.5 | 35.6 | 3.9 | 32.2 | 7.8 |
Oral/XR Naltrexone | 10.4 | 15.4 | 0.3 | 16.8 | 6.4 |
Factor 2 (MAT) | 31.9 | 46.5 | 13.2 | 46.2 | 14.0 |
Physician Visit | 32.8 | 66.4 | 21.9 | 10.6 | 28.6 |
Sober Living Environment | 14.8 | 39.5 | 2.1 | 33.1 | 4.5 |
12 Step Group | 41.2 | 69.7 | 13.8 | 26.6 | na |
None | 5.3 | 0.8 | na | 0 | 22.7 |
Other | 2.2 | na | 2 | 1.4 | na |
Don't know | na | 19.0 | na | na | 51.8 |
Respondents (n=357) were asked about their perception of several treatment options for opioid use disorder. All responses indicate the percent of respondents who aswered "yes" to that form of treatment; respondents could respond to multiple treatment domains per category unless noted. Factor 1 and Factor 2 were determined via principle component analysis and represent at least one endorsed answer in the treatment options listed directly above the factor. na= non-applicable for that category; Oral/XR Naltrexone = oral or injectable extended release naltrexone.
Respondents selected top-rated treatment domain only (as opposed to multiple choice)